Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The newly certified kits are designed for early detection and large-scale screening programs
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The new functionality complements Parse’s existing Evercode immune products
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025
Laurus Labs has reported total income of Rs. 1,784.05 crore during the period ended December 31, 2025
Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
Subscribe To Our Newsletter & Stay Updated